Patents by Inventor Lloyd Tillman
Lloyd Tillman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11859180Abstract: The present disclosure provides compositions comprising an antisense oligonucleotide and one or more excipients that modulates viscosity, turbidity or both viscosity and turbidity. In certain embodiments, compositions comprising an antisense oligonucleotide and one or more excipients having low viscosity are provided. In certain embodiments, compositions comprising an antisense oligonucleotide and one or more excipients having low turbidity are provided. In certain embodiments, pharmaceutical compositions comprising an antisense oligonucleotide and one or more excipients having low viscosity and turbidity are provided.Type: GrantFiled: June 9, 2020Date of Patent: January 2, 2024Assignee: Ionis Pharmaceuticals, Inc.Inventors: Andrew Dibble, Lloyd Tillman, Bret Coldren, Marc Lim
-
Publication number: 20230357768Abstract: A pharmaceutical composition comprising A) one or more ASO or a pharmaceutically acceptable salt thereof; B) one or more permeation enhancer; C) one or more optional pharmaceutically acceptable excipient; and D) one or more optional coating. Said composition for use in the treatment, prevention, or amelioration of a disease associated with PCSK9 or PNPLA3 in a subject.Type: ApplicationFiled: September 16, 2021Publication date: November 9, 2023Inventors: Anna TIVESTEN, Nigel DAVIES, Marie ELEBRING, Peter GENNEMARK, Mariagrazia MARUCCI, Niclas CLEMMENSEN, Hanna MATIC, Okky PUTRA, Pratik Pankaj UPADHYAY, Katrin WALTER, Lloyd TILLMAN, Luis DELLAMARY, Andreas RÃ…DEVIK
-
Publication number: 20210079391Abstract: The present disclosure provides compositions comprising an antisense oligonucleotide and one or more excipients that modulates viscosity, turbidity or both viscosity and turbidity. In certain embodiments, compositions comprising an antisense oligonucleotide and one or more excipients having low viscosity are provided. In certain embodiments, compositions comprising an antisense oligonucleotide and one or more excipients having low turbidity are provided. In certain embodiments, pharmaceutical compositions comprising an antisense oligonucleotide and one or more excipients having low viscosity and turbidity are provided.Type: ApplicationFiled: June 9, 2020Publication date: March 18, 2021Inventors: Andrew Dibble, Lloyd Tillman, Bret Coldren, Marc Lim
-
Publication number: 20190316123Abstract: The present disclosure provides compositions comprising an antisense oligonucleotide and one or more excipients that modulates viscosity, turbidity or both viscosity and turbidity. In certain embodiments, compositions comprising an antisense oligonucleotide and one or more excipients having low viscosity are provided. In certain embodiments, compositions comprising an antisense oligonucleotide and one or more excipients having low turbidity are provided. In certain embodiments, pharmaceutical compositions comprising an antisense oligonucleotide and one or more excipients having low viscosity and turbidity are provided.Type: ApplicationFiled: November 28, 2018Publication date: October 17, 2019Applicant: Ionis Pharmaceuticals, Inc.Inventors: Andrew Dibble, Lloyd Tillman, Bret Coldren, Marc Lim
-
Patent number: 10174318Abstract: The present disclosure provides compositions comprising an antisense oligonucleotide and one or more excipients that modulates viscosity, turbidity or both viscosity and turbidity. In certain embodiments, compositions comprising an antisense oligonucleotide and one or more excipients having low viscosity are provided. In certain embodiments, compositions comprising an antisense oligonucleotide and one or more excipients having low turbidity are provided. In certain embodiments, pharmaceutical compositions comprising an antisense oligonucleotide and one or more excipients having low viscosity and turbidity are provided.Type: GrantFiled: October 14, 2016Date of Patent: January 8, 2019Assignee: Ionis Pharmaceuticals, Inc.Inventors: Andrew Dibble, Lloyd Tillman, Bret Coldren, Marc Lim
-
Publication number: 20170211062Abstract: The present disclosure provides compositions comprising an antisense oligonucleotide and one or more excipients that modulates viscosity, turbidity or both viscosity and turbidity. In certain embodiments, compositions comprising an antisense oligonucleotide and one or more excipients having low viscosity are provided. In certain embodiments, compositions comprising an antisense oligonucleotide and one or more excipients having low turbidity are provided. In certain embodiments, pharmaceutical compositions comprising an antisense oligonucleotide and one or more excipients having low viscosity and turbidity are provided.Type: ApplicationFiled: October 14, 2016Publication date: July 27, 2017Applicant: Ionis Pharmaceuticals, Inc.Inventors: Andrew Dibble, Lloyd Tillman, Bret Coldren, Marc Lim
-
Publication number: 20160002624Abstract: The present disclosure provides compositions comprising an antisense oligonucleotide and one or more excipients that modulates viscosity, turbidity or both viscosity and turbidity. In certain embodiments, compositions comprising an antisense oligonucleotide and one or more excipients having low viscosity are provided. In certain embodiments, compositions comprising an antisense oligonucleotide and one or more excipients having low turbidity are provided. In certain embodiments, pharmaceutical compositions comprising an antisense oligonucleotide and one or more excipients having low viscosity and turbidity are provided.Type: ApplicationFiled: May 17, 2013Publication date: January 7, 2016Applicant: ISIS PHARMACEUTICALS, INC.Inventors: Andrew Dibble, Lloyd Tillman, Bret Coldren, Marc Lim
-
Patent number: 8691785Abstract: The present invention relates to compositions and methods which enhance the local and systemic uptake and delivery of oligonucleotides and nucleic acids via non-parenteral routes of administration. Pharmaceutical compositions comprising oligonucleotides disclosed herein include, for systemic delivery, emulsion and microemulsion formulations for a variety of applications and oral dosage formulations. It has also surprisingly been discovered that oligonucleotides may be locally delivered to colonic sites by rectal enemas and suppositories in simple solutions, e.g., neat or in saline. Such pharmaceutical compositions of oligonucleotides may further include one or more penetration enhancers for the transport of oligonucleotides and other nucleic acids across mucosal membranes.Type: GrantFiled: January 7, 2013Date of Patent: April 8, 2014Assignee: Isis Pharmaceuticals, Inc.Inventors: Ching-Leou Teng, Phillip Dan Cook, Lloyd Tillman, Gregory E. Hardee, David J. Ecker, Muthiah Manoharan
-
Patent number: 8377897Abstract: The present invention relates to compositions and methods which enhance the local and systemic uptake and delivery of oligonucleotides and nucleic acids via non-parenteral routes of administration. Pharmaceutical compositions comprising oligonucleotides disclosed herein include, for systemic delivery, emulsion and microemulsion formulations for a variety of applications and oral dosage formulations. It has also surprisingly been discovered that oligonucleotides may be locally delivered to colonic sites by rectal enemas and suppositories in simple solutions, e.g., neat or in saline. Such pharmaceutical compositions of oligonucleotides may further include one or more penetration enhancers for the transport of oligonucleotides and other nucleic acids across mucosal membranes.Type: GrantFiled: September 28, 2005Date of Patent: February 19, 2013Assignee: Isis Pharmaceuticals, Inc.Inventors: Ching-Leou Teng, Phillip Dan Cook, Lloyd Tillman, Gregory E. Hardee, David J. Ecker, Muthiah Manoharan
-
Publication number: 20070249551Abstract: The present invention relates to compositions and methods which enhance the local and systemic uptake and delivery of oligonucleotides and nucleic acids via non-parenteral routes of administration. Pharmaceutical compositions comprising oligonucleotides disclosed herein include, for systemic delivery, emulsion and microemulsion formulations for a variety of applications and oral dosage formulations. It has also surprisingly been discovered that oligonucleotides may be locally delivered to colonic sites by rectal enemas and suppositories in simple solutions, e.g., neat or in saline. Such pharmaceutical compositions of oligonucleotides may further include one or more penetration enhancers for the transport of oligonucleotides and other nucleic acids across mucosal membranes.Type: ApplicationFiled: September 28, 2005Publication date: October 25, 2007Inventors: Ching-Leou Teng, Phillip Cook, Lloyd Tillman, Gregory Hardee, David Ecker, Muthiah Manoharan
-
Publication number: 20050196443Abstract: Delayed release oral pharmaceutical formulations and methods for enhanced intestinal drug absorption. The formulation comprises a first population of carrier particles comprising a drug and a penetration enhancer which are released at a first location in the intestine, and a second population of carrier particles comprising a penetration enhancer and a delayed release coating or matrix. This penetration enhancer is released at a second location in the intestine downstream from the first location and enhances absorption of the drug when it reaches the second location.Type: ApplicationFiled: December 1, 2004Publication date: September 8, 2005Applicant: ISIS Pharmaceuticals, Inc.Inventors: Susan Weinbach, Lloyd Tillman, Richard Geary, Gregory Hardee
-
Publication number: 20040229831Abstract: The present invention relates to compositions and methods which enhance the local and systemic uptake and delivery of oligonucleotides and nucleic acids via non-parenteral routes of administration. Pharmaceutical compositions comprising oligonucleotides disclosed herein include, for systemic delivery, emulsion and microemulsion formulations for a variety of applications and oral dosage formulations. It has also surprisingly been discovered that oligonucleotides may be locally delivered to colonic sites by rectal enemas and suppositories in simple solutions, e.g., neat or in saline. Such pharmaceutical compositions of oligonucleotides may further include one or more penetration enhancers for the transport of oligonucleotides and other nucleic acids across mucosal membranes.Type: ApplicationFiled: March 4, 2004Publication date: November 18, 2004Applicant: ISIS Pharmaceuticals, Inc.Inventors: Ching-Leou Teng, Phillip Dan Cook, Lloyd Tillman, Gregory E. Hardee, David J, Ecker, Muthiah Manoharan
-
Patent number: 6747014Abstract: The present invention relates to compositions and methods which enhance the local and systemic uptake and delivery of oligonucleotides and nucleic acids via non-parenteral routes of administration. Pharmaceutical compositions comprising oligonucleotides disclosed herein include, for systemic delivery, emulsion and microemulsion formulations for a variety of applications and oral dosage formulations. It has also surprisingly been discovered that oligonucleotides may be locally delivered to colonic sites by rectal enemas and suppositories in simple solutions, e.g., neat or in saline. Such pharmaceutical compositions of oligonucleotides may further include one or more penetration enhancers for the transport of oligonucleotides and other nucleic acids across mucosal membranes.Type: GrantFiled: December 21, 2001Date of Patent: June 8, 2004Assignee: ISIS Pharmaceuticals, Inc.Inventors: Ching-Leou Teng, Phillip Dan Cook, Lloyd Tillman, Gregory E. Hardee, David J. Ecker, Muthiah Manoharan
-
Publication number: 20030040497Abstract: The present invention relates to compositions and methods which enhance the local and systemic uptake and delivery of oligonucleotides and nucleic acids via non-parenteral routes of administration. Pharmaceutical compositions comprising oligonucleotides disclosed herein include, for systemic delivery, emulsion and microemulsion formulations for a variety of applications and oral dosage formulations. It has also surprisingly been discovered that oligonucleotides may be locally delivered to colonic sites by rectal enemas and suppositories in simple solutions, e.g., neat or in saline. Such pharmaceutical compositions of oligonucleotides may further include one or more penetration enhancers for the transport of oligonucleotides and other nucleic acids across mucosal membranes.Type: ApplicationFiled: December 21, 2001Publication date: February 27, 2003Inventors: Ching-Leou Teng, Phillip Dan Cook, Lloyd Tillman, Gregory E. Hardee, David J. Ecker, Muthiah Manoharan